UK markets closed
  • NIKKEI 225

    26,604.84
    -72.96 (-0.27%)
     
  • HANG SENG

    20,116.20
    -55.07 (-0.27%)
     
  • CRUDE OIL

    114.26
    +3.93 (+3.56%)
     
  • GOLD FUTURES

    1,848.50
    +2.20 (+0.12%)
     
  • DOW

    32,637.19
    +516.91 (+1.61%)
     
  • BTC-GBP

    23,481.97
    -230.89 (-0.97%)
     
  • CMC Crypto 200

    642.36
    -18.78 (-2.84%)
     
  • ^IXIC

    11,740.65
    +305.91 (+2.68%)
     
  • ^FTAS

    4,176.59
    +29.51 (+0.71%)
     

Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Orchard Therapeutics (Europe) Limited
Orchard Therapeutics (Europe) Limited

BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results.

A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (866) 374-5140 (toll-free) or +1 (404) 400-0571 (toll) and using the passcode 71474312. A replay of the webcast will be archived on the Orchard website following the presentation.

About Orchard

At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment.

In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard has a deep pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Contacts

Investors

Renee Leck
Director, Investor Relations
+1 862-242-0764
Renee.Leck@orchard-tx.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting